Lycium ruthenicum extract alleviates high-fat diet-induced nonalcoholic fatty liver disease via enhancing the AMPK signaling pathway

Molecular Medicine Reports

Volumn 12, Issue 3, 2015, Pages 3835-3840

  Lin, Jiayao ^a   Zhang, Yu ^a   Wang, Xinqing ^a   Wang, Wenwen ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

AMPK pathway; Lipid accumulation; Lycium ruthenicum extract; Nonalcoholic fatty liver disease

Indexed keywords

ADENYLATE KINASE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FATTY ACID SYNTHASE; GLUCOSE; LIVER PROTECTIVE AGENT; LYCIUM RUTHENICUM EXTRACT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PLANT EXTRACT; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; LIPID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIPID STORAGE; LIPOGENESIS; LIVER PROTECTION; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; ADVERSE EFFECTS; ANIMAL; BLOOD; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; LYCIUM; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PRECLINICAL STUDY;

LYCIUM RUTHENICUM; MUS;

ADENYLATE KINASE; ANIMALS; DIET, HIGH-FAT; DRUG EVALUATION, PRECLINICAL; GLUCOSE; INSULIN RESISTANCE; LIPIDS; LIPOGENESIS; LYCIUM; MALE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; PLANT EXTRACTS; SIGNAL TRANSDUCTION;

EID: 84935513851     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3840     Document Type: Article

References (28)

1. Alba L and Lindor K: Review article: Non-alcoholic fatty liver disease. Aliment Pharmacol Ther 17:977-986, 2003.
2. Jaskiewicz K, Rzepko R and Sledzinski Z: Fibrogenesis in fatty liver associated with obesity and diabetes mellitus type 2. Dig Dis Sci 53:785-788, 2008.
3. Dong H, Lu FE and Zhao L: Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease. Chin J Integr Med 18:152-160, 2012.
4. Wu PS, Wu SJ, Tsai YH, Lin YH and Chao JC: Hot water extracted Lycium barbarum and Rehmannia glutinosa inhibit liver inflammation and fibrosis in rats. Am J Chin Med 39:1173-1191, 2011.
5. Xiao J, Liong EC, Ching Y P, Chang RC, Fung ML, Xu AM, So KF and Tipoe GL: Lycium barbarum polysaccharides protect rat liver from non-alcoholic steatohepatitis-induced injury. Nutr Diabetes 3:e81, 2013.
6. Ni W, Gao T, Wang H, Du Y, Li J, Li C, Wei L and Bi H: Anti-fatigue activity of polysaccharides from the fruits of four Tibetan plateau indigenous medicinal plants. J Ethnopharmacol 150:529-535, 2013.
7. Li J, Li SZ, Feng WJ and Yuan H: In vitro antioxidant and free radical scavenging activities of total flavonoids from the leaves of Lycium ruthenicum Murr. Food Sci 13:061, 2010.
8. Peng Q, Song J, LV X, Wang Z, Huang L and Du Y: Structural characterization of an arabinogalactan-protein from the fruits of Lycium ruthenicum. J Agric Food Chem 60:9424-9429, 2012.
9. Wang JH, Chen XQ and Zhang WJ: Study on hypoglycemic function of polysaccharides from Lycium ruthenicum Murr. fruit and its mechanism. Food Sci 30:244-248, 2009.
10. Guo S, Copps KD, Dong X, Park S, Cheng Z, Pocai A, Rossetti L, Sajan M, Farese RV and White MF: The Irs1 branch of the insulin signaling cascade plays a dominant role in hepatic nutrient homeostasis. Mol Cell Biol 29:5070-5083, 2009.
11. Malaguarnera M, Di Rosa M, Nicoletti F and Malaguarnera L: Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl) 87:679-695, 2009.
12. Musso G, Gambino R and Cassader M: Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 48:1-26, 2009.
13. Bijland S, Mancini SJ and Salt IP: Role of AMP-activated protein kinase in adipose tissue metabolism and inflammation. Clin Sci 124:491-507, 2013.
14. Cohen JC, Horton JD and Hobbs HH: Human fatty liver disease: Old questions and new insights. Science 332:1519-1523, 2011.
15. Rahimi RS and Landaverde C: Nonalcoholic fatty liver disease and the metabolic syndrome: Clinical implications and treatment. Nutr Clin Pract 28:40-51, 2013.
16. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML and Clore JN: Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120:1183-1192, 2001.
17. Utzschneider KM and Kahn SE: Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 91:4753-4761, 2006.
18. Serviddio G, Bellanti F and Vendemiale G: Free radical biology for medicine: Learning from nonalcoholic fatty liver disease. Free Radic Biol Med 65:952-968, 2013.
19. Shimano H, Yahagi N, Amemiya-Kudo M, Hasty AH, Osuga J, Tamura Y, Shionoiri F, Iizuka Y, Ohashi K, Harada K, Gotoda T, et al: Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J Biol Chem 274:35832-35839, 1999.
20. Matsumoto M, Ogawa W, Akimoto K, Inoue H, Miyake K, Furukawa K, Hayashi Y, Iguchi H, Matsuki Y, Hiramatsu R, Shimano H, et al: PKClambda in liver mediates insulin-induced SREBP-1c expression and determines both hepatic lipid content and overall insulin sensitivity. J Clin Invest 112:935-944, 2003.
21. Rakhshandehroo M, Knoch B, Müller M and Kersten S: Peroxisome proliferator-activated receptor alpha target genes. PPAR Res 2010:612089, 2010.
22. Reddy JK and Rao MS: Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 290:G852-G858, 2006.
23. Cao H, Maeda K, Gorgun CZ, Kim HJ, Park SY, Shulman GI, Kim JK and Hotamisligil GS: Regulation of metabolic responses by adipocyte/macrophage fatty acid-binding proteins in leptin-deficient mice. Diabetes 55:1915-1922, 2006.
24. Ahmed MH and Byrne CD: Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). Drug Discov Today 12:740-747, 2007
25. Kohjima M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, Yada M, Yada R, Harada N, Enjoji M, Takayanagi R and Nakamuta M: SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int J Mol Med 21:507-511, 2008.
26. Barroso E, Rodriguez-Calvo R, Serrano-Marco L, Astudillo AM, Balsinde J, Palomer X and Vasquez-Carrera M: The PPARβ/δ activator GW501516 prevents the down-regulation of AMPK caused by high-fat diet in liver and amplifies the PGC-1α-lipin 1-PPARα pathway leading to increased fatty acid oxidation. Endocrinology 152:1848-1859, 2011.
27. Viollet B, Athea Y, Mounier R, Guigas B, Zarrinpashneh E, Horman S, Lantier L, Hebrard S, Devin-Leclerc J, Beauloye C, Foretz M, et al: AMPK: Lessons from transgenic and knockout animals. Front Biosci (Landmark Ed) 14:19-44, 2009
28. Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, Park O, Luo Z, Lefai E, Shyy JY, Gao B, et al: AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 13:376-388, 2011.